Abstract：Objective To compare the long-term efficacy and comprehensive quality of life between Agomelatine and Paroxetine in the patients with depression.Methods A total of 64 patients with depression who were hospitalized in the Department of Psychiatry,Shandong Daizhuang Hospital from March 2018 to March 2020 were selected as the research subjects,and they were divided into study group (33 cases) and control group (31 cases) by coin toss method.Patients in the study group were treated with agomelatine Antidepressant,and patients in the control group were treated with Paroxetine antidepressant.The clinical rehabilitation effects of the two groups were compared by Hamilton depression scale (HAMD) and medical outcomes study short-form 36 (SF-36) at admission,discharge and 1 year after discharge,respectively.Results At admission and discharge,there were no statistically significant differences in HAMD and SF-36 scores between the two groups (P＞0.05).One year after discharge,the total HAMD score in the study group was lower than that in the control group,the difference was statistically significant (P＜0.05).One year after discharge,the total score of SF-36 in the study group was higher than that in the control group,the difference was statistically significant(P＜0.05).Conclusion Agomelatine has better long-term efficacy than Paroxetine in the treatment of depression,it can not only improve the clinical symptoms effectively and stabilize the condition,but also has advantages in improving the quality of life.
申连城；李遵清； 李龙飞；李明真；韩鹏. 阿戈美拉汀与帕罗西丁对抑郁症的远期疗效及综合生活质量的比较研究[J]. 中国当代医药, 2022, 29(22): 70-73.
SHEN Liancheng1 LI Zunqing1 LI Longfei1 LI Mingzhen2 HAN Peng. Comparative study of long-term efficacy and comprehensive quality of life between Agomelatine and Paroxetine in the patients with depression. 中国当代医药, 2022, 29(22): 70-73.
京公网安备 11010502046607号